i-Pharm Consulting

Rare diseases are placing increasing strain on healthcare systems. Over 7,000 rare diseases are identified and the demand for specialised expertise in this field has never been higher. But, finding the right people for these jobs can be a lengthy process. Specialised recruitment services can accelerate your hiring process by up to 60% while ensuring exceptional candidate quality. Check out below how life science recruitment firms can help streamline your hiring and staffing process.👇 _____________ Read our full blog post on the topic here: 🔗 https://lnkd.in/e43cEeAT #lifesciences #raredisease #iPharm

The clinical trials landscape in Australia is seeing significant shifts and advancements, with the recent boom being driven by government incentives and increased investments. 🚀 Here are some key trends shaping the future: 1️⃣ Higher Standards: Enhanced standards are being introduced as complex trials become more common, ensuring top-tier research across the nation. 2️⃣ Top Talent: Experienced leaders from CROs and pharma are joining Trial Site Networks, optimising operations and driving best practices. 3️⃣ Proliferation of Trial Sites: There's a surge in the establishment and expansion of state-of-the-art trial sites, equipped with advanced technology. 4️⃣ Global Leadership: With ongoing investments and strategic acquisitions, Australia is positioning itself at the forefront of clinical research and patient care. _________________ How do you think these changes will impact the future of clinical trials in Australia? Cast your vote below! #clinicaltrials #iPharm #iPharmInsights

The clinical trials landscape in Australia is set for another leap forward, driven by quality and innovation as Trial Site Networks continue to evolve. 🌱 So, what changes can we expect to see? 🤔 1️⃣ Higher Standards: With more complex and sophisticated studies on the horizon, there’s a focus on raising the bar across the board. Enhanced standards are attracting cutting-edge trials, ensuring top-tier research is conducted nationwide. 2️⃣ Top Talent Driving Change: We’re seeing a wave of experienced leaders from CROs and pharma entering Trial Site Networks, bringing invaluable expertise to optimise operations and ensure best practices. 3️⃣ A Global Leader in the Making: With continued investment and strategic acquisitions, Australia is positioning itself as a world leader in clinical trials, offering unmatched opportunities for innovation and patient care. ________________ Want to read more on the topic? Take a look at our August edition of i-Pharm Insights here: 🔗 https://lnkd.in/exr6Sp-f #iPharm #iPharmInsights #trialsitenetworks

Happy Labor Day! 🇺🇸 We are wishing all of our clients, candidates, friends, and family a very Happy Labor Day celebration. We hope you enjoy a well-deserved break, filled with relaxation, good company, and a moment to reflect on the hard work that drives us all forward. 💪 The i-Pharm Team. #LaborDay #iPharm

Australia’s biotechnology sector is undergoing a significant transformation, driven by a surge in clinical trial activity since 2020.🔬 At the heart of this evolution is the Australian government’s tax incentive programme, which has made the country a hotspot for biotech companies. This has led to the rapid emergence of Trial Site Networks, reshaping the clinical research landscape. Some of the key developments in the transformation are: 1️⃣ Proliferation of Trial Sites: There’s a notable increase in the establishment of state-of-the-art Phase I trial sites, equipped with advanced hospital settings and cutting-edge technology. 2️⃣ Expansion and Growth: Existing trial sites are scaling up to meet growing demand, with strategic acquisitions fuelling this growth. Investors are focusing on acquiring and consolidating standalone sites, expanding the reach of Trial Site Networks beyond major metropolitan areas. _________________ Want to read more on the topic? Check out August's edition of i-Pharm Insights here: 🔗 https://lnkd.in/exr6Sp-f #iPharm #iPharmInsights #trialsitenetworks

August's edition of i-Pharm Insights is here! 🗞️ This month, we're turning our attention to a dynamic and rapidly growing sector within the Australian market: Trial Site Networks. We delve into the factors fueling this growth, the strategic moves reshaping the sector, and the leadership that is driving these changes. We also explore the broader implications for the clinical trials market in Australia and beyond. _________________ Click below to read the full newsletter! ⬇️ #iPharmInsights #trialsitenetworks #clinicaltrial

Last week, we asked for your opinions on BiologIC Technologies' innovative space medicine project. The project offers a £65 million investment that could revolutionise healthcare, aging research and sustainable production in space. 🚀 The votes are in, and with faster medical breakthroughs being voted for as the most compelling aspect of the research, we are hopeful for drug development and medical development within our industry. ___________________ Leave your thoughts on these results in the comments below. 💬 #spaceinnovation #biotech #iPharm

Yesterday, we looked at a new survey in the biopharma industry that looked at the increasing importance of sustainability. Now, we wanted to look at some challenges that are facing the incorporation of sustainable practices. 🔎 Weak collaboration across the value chain and difficulties in accurately measuring the financial impact of sustainability efforts are major obstacles. 64% of survey respondents believe that failing to meet sustainability targets poses a critical threat to their business. Moreover, 69% of survey participants report that collaboration on sustainability strategies is insufficient, and 76% struggle with accurately forecasting the financial impact of these initiatives. These findings underscore the urgent need for the industry to enhance its collaborative efforts and develop more reliable metrics to measure progress. 🌱 ___________ How do you see sustainability impacting the future of the biopharma industry? Comment your thoughts below! #sustainability #biopharma #iPharm

Sustainability is more than just a goal, it's becoming a defining factor in the biopharma industry. 🌍 A recent comprehensive survey of over 800 biopharma executives highlights the growing importance of sustainability, with 62% of companies identifying it as a top priority. The benefits are clear: improved brand reputation, increased profits, higher share prices, and enhanced talent attraction. Executives like David Butler of Hongene Biotech emphasise the strategic and financial sense of pursuing sustainable practices, citing long-term cost savings as a key driver. The potential rewards for companies, and for the planet are immense. ______________ Do you see any challenges that could come with these opportunities? Comment your thoughts below! #biopharma #iPharm #sustainability

Last week, we looked at cresomycin, a new synthetic antibiotic developed by researchers at the University of Illinois Chicago and Harvard University. We asked for your opinions on how do you think synthetic antibiotics like cresomycin will impact the future of medicine. 💊 The results are in, 48% of you thought it was too early to tell, and 26% think it is useful, but not a game changer. This cautious approach is telling of our industry, where precaution is essential for steady growth. Leave your thoughts on these results in the comments! 💬 #iPharm #antibiotic #drugdevelopment